Literature DB >> 2473661

HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma.

B R Smoller1, N S McNutt, A Hsu.   

Abstract

Dysplastic nevi are melanocytic tumors that occupy intermediate positions in the spectrum of melanocytic proliferations. Although they are invariably cured if completely excised, their biologic potential if left untreated is unknown. We examined a series of such lesions with HMB-45, a melanocyte-specific antibody, in order to explore protein expression within these borderline lesions. HMB-45 has previously been shown to label intraepidermal melanocytes within melanomas and within all nevi. Intradermal melanoma cells also label with HMB-45, but dermal nevus cells within common melanocytic nevi do not normally stain. In contrast, we found mild to moderate staining of nevus cells within the papillary dermis of dysplastic nevi and within residual nevus cells adjacent to malignant melanomas. In the same lesions, we demonstrated strong staining of intraepidermal melanocytes. Thus, dermal nevus cells within dysplastic nevi and within residual nevus cells adjacent to malignant melanomas are expressing low-level amounts of a protein expressed by melanoma cells, but not by dermal nevus cells within wholly benign melanocytic tumors. This lends support to the concept of these lesions as precursor lesions with undetermined biologic potential.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473661     DOI: 10.1097/00000478-198908000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  The ultrastructure of dysplastic naevi: comparison with superficial spreading melanoma and common naevocellular naevi.

Authors:  K Langer; K Rappersberger; A Steiner; K Konrad; K Wolff
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Expression of Bcl-2, Melan A and HMB-45 in Dysplastic Nevi.

Authors:  Oana Maria Patrascu; Mariana Costache; Adrian Vasile Dumitru; Corina Nicoleta Mehotin; Maria Sajin; Anca Mihaela Lazaroiu
Journal:  Maedica (Bucur)       Date:  2016-03

Review 3.  Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 4.  Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis.

Authors:  Costantino Ricci; Emi Dika; Francesca Ambrosi; Martina Lambertini; Giulia Veronesi; Corti Barbara
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

5.  Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s).

Authors:  E M Petty; L H Gibson; J W Fountain; J L Bolognia; T L Yang-Feng; D E Housman; A E Bale
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

6.  C-myc oncogene expression in ocular melanomas.

Authors:  J A Royds; R M Sharrard; M A Parsons; J Lawry; R Rees; D Cottam; B Wagner; I G Rennie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

7.  Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.

Authors:  Bonnie E Gould Rothberg; Christopher B Moeder; Harriet Kluger; Ruth Halaban; David E Elder; George F Murphy; Alexander Lazar; Victor Prieto; Lynn McDivitt Duncan; David L Rimm
Journal:  Mod Pathol       Date:  2008-06-13       Impact factor: 7.842

8.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.